Tag: sparsentan
-
Renalys Pharma Reports Positive Phase III Topline Results for Sparsentan in Japanese IgA Nephropathy Patients
Positive topline results in Japanese IgA nephropathy trial Renalys Pharma announced positive topline data from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy (IgAN). The trial enrolled 35 participants and was designed to assess the efficacy and safety of sparsentan, a dual-acting agent targeting both the endothelin and angiotensin receptor pathways,…
-
Sparsentan Phase III IgA Nephropathy in Japan: Positive Results
Groundbreaking Phase III topline results for Sparsentan in Japanese IgA nephropathy patients Renalys Pharma has announced positive topline results from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy. The trial, conducted in a cohort of 35 patients, focused on the primary endpoint of the percent change from baseline in the 24-hour…
-
Sparsentan Delivers Positive Phase 3 Results in Japanese IgA Nephropathy
Overview: sparsentan earns positive topline data in Japanese IgA nephropathy Renalys Pharmaceutical Co. announced encouraging topline results from a Phase 3 study evaluating sparsentan, a dual-acting agent, in Japanese patients with IgA nephropathy (IgAN). The trial focused on the safety and efficacy of sparsentan in a specific, well-defined cohort (N=35) and sought to determine whether…